

Conference Learning Objectives

- Analyze the latest advancements in cardiovascular and metabolic disease
- Interpret and apply current cardiovascular guidelines
- Evaluate clinical trial results and their impact on patient care

Conference Date & Time

SESSION 1

Wednesday, June 3rd
(7:00 - 9:00 pm EDT)

SESSION 2

Wednesday, June 10th
(7:00 - 9:00 pm EDT)

SESSION 3

Wednesday, June 17th
(7:00 - 9:00 pm EDT)

Conference Co-Chairs



Milan Gupta

MD, FRCPC, FCCS, CPC(HC)
Assistant Professor,
Department of Medicine,
University of Toronto
Medical Director,
Collaborative CME & Research Network
Brampton, ON



Liam Brunham

MD, PhD, FRCPC, FNLA
University of British Columbia
Internal Medicine Specialist -Lipids
Vancouver, BC

Program Agenda

SESSION 1 - Wednesday, June 3rd (7:00-9:00 pm EDT)

Faculty

- 7:00 PM **Welcome and Introductions**
- 7:10 PM Gender differences in CV risk factors, disease and management Martha Gulati
- 7:30 PM Workup and treatment of resistant hypertension Nadia Khan
- 7:50 PM What you need to know about metabolic dysfunction-associated steatotic liver disease (MASLD) Alnoor Ramji
- 8:10 PM HFpEF diagnosis and management in primary care Justin Ezekowitz
- 8:30 PM Q&A
- 9:00 PM **Closing Comments**

SESSION 2 - Wednesday, June 10th (7:00-9:00 pm EDT)

- 7:00 PM **Welcome and Introductions**
- 7:10 PM Detection and management of ATTR in primary care Margot Davis
- 7:30 PM New frontiers: Will CV inflammation be a treatment target? Shaun Goodman
- 7:50 PM GLP-1 therapies: Applications in cardiovascular disease Milan Gupta
- 8:10 PM Are we under-treating chronic kidney disease? Navdeep Tangri
- 8:30 PM Q&A
- 9:00 PM **Closing Comments**

SESSION 3 - Wednesday, June 17th (7:00-9:00 pm EDT)

- 7:00 PM **Welcome and Introductions**
- 7:10 PM Where does bempedoic acid fit in my practice? Liam Brunham
- 7:30 PM Familial Chylomicronemia Syndrome: Recognition and Treatment Daniel Gaudet
- 7:50 PM New frontiers: Where will oral PCSK9 inhibitors fit in clinical practice Milan Gupta
- 8:10 PM Intensive LDL-C reduction across the spectrum of ASCVD: Applying new guidelines to clinical practice Marc Sabatine
- 8:30 PM Q&A
- 9:00 PM **Closing Comments**

This program has been developed by CCRN and has received unrestricted educational grants and in-kind support from:

Alnylam Pharmaceuticals, Amgen, Arrowhead Pharmaceuticals, AstraZeneca, Bayer, HLS Therapeutics, Merck, Novo Nordisk



Program Agenda

Time	Topic	Learning Objective	Faculty
SESSION 1 - Wednesday, June 3rd (7:00-9:00 pm EDT)			
7:00 - 7:10 PM	Welcome and Introductions		
7:10 - 7:30 PM	Gender differences in CV risk factors, disease and management	Recognize sex-related differences in cardiovascular risk, presentation, and treatment outcomes to improve prevention and management	Martha Gulati
7:30 - 7:50 PM	Workup and treatment of resistant hypertension	Identify patients with resistant hypertension and evaluate the role of the aldosterone pathway and emerging targeted therapies	Nadia Khan
7:50 - 8:10 PM	What you need to know about metabolic dysfunction-associated steatotic liver disease (MASLD)	Recognize the link between MASLD and cardiovascular risk and apply cardiometabolic risk-reduction strategies	Alnoor Ramji
8:10 - 8:30 PM	HFpEF diagnosis and management in primary care	Recognize HFpEF in primary care and apply current diagnostic strategies and therapies that improve patient outcomes	Justin Ezekowitz
8:30 - 9:00 PM	Q&A		
9:00 PM	Closing Comments		
SESSION 2 - Wednesday, June 10th (7:00-9:00 pm EDT)			
7:10 - 7:10 PM	Welcome and Introductions		
7:10 - 7:30 PM	Detection and management of ATTR in primary care	Identify clinical features that should prompt evaluation for transthyretin amyloidosis and initiate appropriate referral and management pathways	Margot Davis
7:30 - 7:50 PM	New Frontiers: Will CV Inflammation be a treatment target?	Evaluate emerging evidence linking inflammation to cardiovascular disease and its potential implications for future patient care	Shaun Goodman
7:50 - 8:10 PM	GLP-1 therapies: Applications in cardiovascular disease	Apply cardiovascular outcomes evidence for GLP-1 receptor agonists to reduce cardiovascular risk in patients with obesity or cardiometabolic disease	Milan Gupta

This program has been developed by CCRN and has received unrestricted educational grants and in-kind support from:

Alnylam Pharmaceuticals, Amgen, Arrowhead Pharmaceuticals, AstraZeneca, Bayer, HLS Therapeutics, Novo Nordisk, Merck



Program Agenda

Time	Topic	Learning Objective	Faculty
SESSION 2 - Wednesday, June 10th (7:00-9:00 pm EDT)			
8:10 - 8:30 PM	Are we under-treating chronic kidney disease?	Recognize chronic kidney disease in patients at cardiovascular risk and apply evidence-based therapies that reduce cardiovascular events and slow disease progression	Navdeep Tangri
8:30 - 9:00 PM	Q&A		
9:00 PM	Closing Comments		
SESSION 3 - Wednesday, June 17th (7:00-9:00 pm EDT)			
7:00 - 7:10 PM	Welcome and Introductions		
7:10 - 7:30 PM	Where does bempedoic acid fit in my practice?	Apply recent evidence to determine when bempedoic acid should be added to lipid-lowering therapy	Liam Brunham
7:30 - 7:50 PM	Familial Chylomicronemia Syndrome: Recognition and Treatment	Identify patients with severe hypertriglyceridemia suggestive of familial chylomicronemia syndrome and apply appropriate management strategies	Daniel Gaudet
7:50 - 8:10 PM	New frontiers: Where will oral PCSK9 inhibitors fit in clinical practice	Evaluate emerging evidence for oral PCSK9-targeting therapies and their potential role in lipid management	Milan Gupta
8:10 - 8:30 PM	Intensive LDL-C reduction across the spectrum of ASCVD: Applying new guidelines to clinical practice	Apply current guidelines and emerging evidence to support intensive LDL-C reduction across the spectrum of ASCVD.	Marc Sabatine
8:30 - 9:00 PM	Q&A		
9:00 PM	Closing Comments		

This program has been developed by CCRN and has received unrestricted educational grants and in-kind support from:

Anylam Pharmaceuticals, Amgen, Arrowhead Pharmaceuticals, AstraZeneca, Bayer, HLS Therapeutics, Novo Nordisk, Merck